Table 2.
Incidence per 1000 person-years and hazard ratios of gastric cancer development between histamine-2 receptor antagonist and proton pump inhibitor user group according to the duration of medication.
| Study Subjects | N | Case | Incidence | Unadjusted HR (95% CI) | Adjusted HR (95% CI) |
p-Value |
|---|---|---|---|---|---|---|
| (For more than) 60 days | ||||||
| H2RA | 5006 | 23 | 1.13 | 1.00 (ref) | 1.00 (ref) | |
| PPI | 5006 | 28 | 1.43 | 1.29 (0.74–2.24) | 1.30 (0.75–2.27) | 0.348 |
| 90 days | ||||||
| H2RA | 2919 | 13 | 1.16 | 1.00 (ref) | 1.00 (ref) | |
| PPI | 2919 | 11 | 1.12 | 0.98 (0.44–2.22) | 0.98 (0.43–2.22) | 0.961 |
| 120 days | ||||||
| H2RA | 1883 | 11 | 1.64 | 1.00 (ref) | 1.00 (ref) | |
| PPI | 1883 | 7 | 1.21 | 0.81 (0.31–2.12) | 0.81 (0.31–2.14) | 0.677 |
| 180 days | ||||||
| H2RA | 1003 | 8 | 2.34 | 1.00 (ref) | 1.00 (ref) | |
| PPI | 1003 | 1 | 0.37 | 0.18 (0.02–1.45) | 0.19 (0.02–1.53) | 0.119 |
H2RA, histamine-2 receptor antagonist; PPI, proton pump inhibitor; HR, hazard ratio; CI, confidence interval.